Avanzanite Bioscience enhances access to orphan drugs in Europe, partnering with pharma for rare disease treatments.
Avanzanite Bioscience has raised $37.1M in total funding. The most recent round was Series A. The last funding was announced in November 2025.
Avanzanite Bioscience's investors include MVM Life Science Partners.
Avanzanite Bioscience is headquartered in Amsterdam, The Netherlands.
Avanzanite Bioscience enhances access to orphan drugs in Europe, partnering with pharma for rare disease treatments.
Avanzanite Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Avanzanite Bioscience — Funding & Investors." VCBacked, November 18, 2025, https://www.vcbacked.co/company/avanzanite-bioscience. Accessed October 31, 2026.
VCBacked. (2025). Avanzanite Bioscience — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/avanzanite-bioscience
{{cite web |title=Avanzanite Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/avanzanite-bioscience |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated